New insider activity at Solid Biosciences ( (SLDB) ) has taken place on February 22, 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Perceptive Advisors Llc, a significant shareholder, has made a substantial investment in Solid Biosciences by purchasing 5,000,000 shares of the company’s stock. This purchase is valued at $20,150,000.
Recent Updates on SLDB stock
Solid Biosciences experienced positive developments as Chardan raised its price target for the company based on promising initial clinical data from the Phase 1/2 INSPIRE DUCHENNE trial. The trial of SGT-003 showed strong vector transduction and microdystrophin expression, improvements in muscle integrity biomarkers, and potential cardiac benefits. These encouraging activity signals, along with acceptable safety results, led the firm to increase its probability of success for the program to 48%. Additionally, a secondary share offering was priced at $4.03, reflecting investor interest. These advancements contributed to a more optimistic outlook for Solid Biosciences, supported by anticipated trial data and the company’s gene therapy platform.
More about Solid Biosciences
YTD Price Performance: 53.85%
Average Trading Volume: 2,085,287
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $457.9M
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue